Buprenorphine and Schisandra Sphenanthera: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Schisandra Sphenanthera
No brand names on record
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Schisandra is an herbal supplement that can slow down a liver enzyme (called CYP3A4) that your body uses to break down buprenorphine. When that enzyme is slowed, buprenorphine can build up higher than usual in your blood.
That means your buprenorphine could act stronger or last longer than expected. The main things to watch for are too much drowsiness, feeling very sedated, or slow, shallow breathing. Please don't change either one on your own. Let your pharmacist or doctor know you're taking both, they can adjust your dose and keep a closer eye on you so you stay safe and comfortable.
Mechanism: Schisandra sphenanthera inhibits CYP3A4, the enzyme responsible for buprenorphine metabolism. Buprenorphine is not a prodrug, so inhibition raises its plasma concentrations (increased AUC/Cmax) and increases the risk of opioid-related adverse events.
- Effect: increased buprenorphine exposure, prolonged opioid effect, risk of sedation and respiratory depression.
- Severity/Evidence: major; probable substantiation. Onset unspecified.
- Management: if the inhibitor is needed, consider reducing the buprenorphine dose until stable, monitor frequently for sedation/respiratory depression. On inhibitor discontinuation, watch for withdrawal and consider dose increase. For subQ formulations, monitor for over-medication or, conversely, adequacy of levels after conversion. Use formulations permitting precise titration when needed.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Because plasma buprenorphine concentrations rise when buprenorphine is given together with a CYP3A4 inhibitor, extended opioid effects such as respiratory depression can result. When a CYP3A4 inhibitor must be introduced in someone already taking buprenorphine, it may be advisable to lower the buprenorphine dose until drug effects stabilize, with frequent monitoring for sedation and respiratory depression. Conversely, if a CYP3A4 inhibitor is stopped in a patient on buprenorphine, an increase in the buprenorphine dose may be warranted until effects stabilize, along with monitoring for opioid withdrawal signs2. When dosage cannot be modified once the CYP3A4 inhibitor is absent, the patient should be switched back to a buprenorphine formulation that allows finer dose titration. For patients transitioned from transmucosal buprenorphine taken alongside CYP3A4 inhibitors, confirm through monitoring that the plasma buprenorphine level delivered by subQ buprenorphine is sufficient. For patients already receiving subQ buprenorphine who then need a CYP3A4 inhibitor, watch for indications of over-medication. Should signs and symptoms of buprenorphine toxicity or overdose develop while the co-administered drug cannot be lowered or stopped, decrease the buprenorphine dose. If the doses on hand do not allow the target dose to be reached, stop the treatment and manage the patient with a buprenorphine formulation that permits more precise dose adjustments1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments and monitoring.
- Tell your pharmacist and prescriber you are using Schisandra, since supplements are easy to overlook.
- Your buprenorphine dose may need to be adjusted and individualized by your care team, and they may monitor you more closely for sedation and breathing changes.
- If you later stop the Schisandra, tell your team, because your dose may need to go back up and they will watch for withdrawal.
- Get help right away for extreme drowsiness or slow, shallow breathing.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of concurrently administered CYP3A4 inhibitors on buprenorphine exposure in patients receiving subQ buprenorphine has not been investigated; nevertheless, these interactions have been documented in studies employing transmucosal buprenorphine. The effects of buprenorphine may vary according to the route of administration 1.
Common questions
Can I take Buprenorphine and Schisandra Sphenanthera together?
Schisandra can raise buprenorphine levels by slowing its breakdown, increasing the risk of sedation and slowed breathing; tell your pharmacist or doctor so they can adjust your dose and monitor you. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Buprenorphine and Schisandra Sphenanthera interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Buprenorphine and Schisandra Sphenanthera interaction managed?
Keep taking both as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments and monitoring. Tell your pharmacist and prescriber you are using Schisandra, since supplements are easy to overlook. Your buprenorphine dose may need to be adjusted and individualized by your care team, and they may monitor you more closely for sedation and breathing… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Buprenorphine or Schisandra Sphenanthera need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Schisandra Sphenanthera
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist